论文部分内容阅读
目的探讨缬沙坦治疗扩张型心肌病的临床疗效。方法将52例扩张型心肌病患者随机分成治疗组和对照组,两组患者均给予休息、限盐、吸氧、利尿、强心、扩血管、血管紧张素转换酶抑制剂、营养心肌细胞等常规治疗,治疗组在此基础上加服缬沙坦,观察并比较两组患者治疗前后的临床疗效及心功能指标的变化。结果治疗组患者的临床效果(总有效率65.38%)要明显优于对照组患者的临床效果(总有效率84.62%);治疗组在左心室舒张末期内径、左心室收缩末期内径及左室射血分数等心功能指标的改善上明显优于对照组。结论缬沙坦在治疗扩张型心肌病上是安全有效的,值得在临床推广。
Objective To investigate the clinical efficacy of valsartan in the treatment of dilated cardiomyopathy. Methods Fifty-two patients with dilated cardiomyopathy were randomly divided into treatment group and control group. Both groups were given rest, salt restriction, oxygen inhalation, diuretic, cardiac, vasodilator, angiotensin converting enzyme inhibitor, cardiomyocyte, etc. On the basis of this, valsartan was added to the treatment group. The clinical efficacy and changes of cardiac function before and after treatment were observed and compared. Results The clinical effect (total effective rate 65.38%) in the treatment group was significantly better than that in the control group (total effective rate 84.62%). The left ventricular end diastolic diameter, left ventricular end-systolic diameter and left ventricular ejection fraction Blood and other cardiac function indicators improved significantly better than the control group. Conclusion Valsartan in the treatment of dilated cardiomyopathy is safe and effective, it is worth in the clinical promotion.